Clinical Trial Update: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating CART-19 T cell therapy targeting CD19 in patients with relapsed or refractory acute myeloid leukemia (AML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CART-19 T cell Therapy (CD19-directed CAR-T cell)

Snippet

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN